ARTICLE | Finance

Ebb & Flow

June 28, 2004 7:00 AM UTC

When FDA grants Fast Track designation or an SPA, investors need to remember that the FDA action is related to an indication where there's unmet need on the one hand, or to a trial design on the other - not to the compound being tested.

A case in point is IntraBiotics (IBPI), whose stock had more than tripled from $3.72 since it received Fast Track designation last September for its iseganan to prevent ventilator-associated pneumonia (see "IBPI's Round Trip"). ...